CD34 and lymphoma: Overall, Plerixafor led to a 7-fold increase in CD34+ cell numbers in peripheral blood in the entire cohort (myeloma and lymphoma patients) with a significantly greater increase in myeloma than in lymphoma patients (8-fold vs. 4-fold, p < 0.001).